What Parkwalk Advisors does

Parkwalk Advisors Ltd is a London-based venture capital and investment management firm founded in 2009 that specialises in backing deep technology companies spun out of UK universities and research institutions. Operating as a wholly-owned subsidiary of IP Group plc, the firm manages Enterprise Investment Scheme (EIS) funds that provide tax-efficient investment vehicles for UK-resident investors while channeling capital into spinouts across sectors including AI, quantum computing, hardware, materials, cleantech, digital health, life sciences, medtech, and agtech. As of April 2026, Parkwalk reported having backed over 200 companies and raising more than £1 billion in cumulative funding across its portfolio, and Beauhurst ranked it the UK's most active investor in university spinouts in 2025.

Parkwalk invests across the spinout lifecycle from pre-seed to scale, almost always as a participating or co-leading investor alongside institutional partners such as Oxford Science Enterprises, Cambridge Enterprise Ventures, UK Innovation and Science Seed Fund (UKI2S), Northern Gritstone, and the Development Bank of Wales. The firm's deal flow is sourced through embedded relationships with major UK universities and their technology transfer offices (Oxford, Cambridge, UCL, Manchester, and the National Physical Laboratory), giving it preferential access to academic IP at the point of commercialisation. Recent notable investments include Quantum Motion ($160M Series C, 2026), Brainomix (AI medical imaging, £18.8M Series C, 2026), Phasecraft ($34M Series B quantum software, 2025), and Scripta Therapeutics ($12M AI/biology seed, 2025). The firm is regulated by the UK Financial Conduct Authority (FRN: 502237) and is registered in England and Wales at 3 Pancras Square, King's Cross.

The business model is fund management: Parkwalk generates revenue through management fees on EIS-registered fund vintages and carried interest on successful exits, with its offerings explicitly restricted to UK residents. Distribution is direct to high-net-worth and sophisticated investors via the firm's investor relations team, with co-investment opportunities available for direct stakes in individual portfolio companies. The firm employs 11-50 staff organised around investment, business development, sales/marketing, finance, and legal functions. Strategic positioning emphasises specialist origination in UK academic spinouts rather than competing head-on with generalist VCs, with the value proposition to LPs anchored in EIS tax relief plus exposure to deeptech companies at the seed-to-scale boundary.

Name

Parkwalk Advisors

Legal name

Parkwalk Advisors Ltd

Website

https://parkwalkadvisors.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Parkwalk Advisors is a London-based VC firm that invests in deeptech spinouts from UK universities across AI, quantum, healthtech, and cleantech. Part of IP Group plc, it manages EIS funds for UK investors and has backed over 200 portfolio companies.

Ownership category

akta.pro rank

Product category

Venture Capital and Private Equity (University Spinout Investment)

NAICS

Portfolio Management and Investment Advice (52394), All Other Financial Investment Activities (52399), Other Financial Vehicles (52599)

SIC

Investment Advice (6282), Finance Services (6199)

akta.pro primary industry

Emerging Managers / Seeding Platforms (FSAHAKAI)

akta.pro secondary industry

Equity Capital Advisory (Private Equity Placements, Growth Capital) (BPAHAOAE)

Keywords

• Venture capital investing
• University spinout funding
• EIS fund management
• Deeptech seed investing
• UK technology transfer

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others

Distribution channels3 records

Marketing channels3 records

Core offering

Parkwalk Advisors is an FCA-regulated investment management firm that raises and deploys capital through Enterprise Investment Scheme (EIS) funds into early-stage UK university spinouts developing deeptech in AI, quantum computing, hardware, materials, digital health, life sciences, medtech, agtech and cleantech. The firm invests across the spinout lifecycle from seed to scale and additionally offers co-investment opportunities for investors wanting direct stakes in individual portfolio companies.

Product overview

Parkwalk Advisors is a venture capital and investment management firm, not a product/technology company. It operates as an EIS (Enterprise Investment Scheme) fund manager that invests in UK university spinouts across deeptech sectors including AI, Quantum Computing, Hardware, Cleantech, Digital Health, and Life Sciences. The firm provides funding, expertise, and networks to help convert academic research into commercial innovations. The company manages investment funds and offers tax-efficient investment opportunities to investors, functioning as a fund manager rather than a product or service provider to end customers.

Differentiator

Problem solved

Functional benefit

Products and services

• EIS Investment Funds Tax-efficient Enterprise Investment Scheme (EIS) fund products for UK resident investors seeking exposure to UK university spinouts, offering capital gains tax relief, income tax relief and inheritance tax planning benefits. Parkwalk has been recognised as Best EIS Investment Manager at the Growth Investor Awards 2025.
• Co-Investment Opportunities Direct co-investment opportunities for qualified investors wanting to take direct stakes in individual UK university spinout portfolio companies alongside Parkwalk's EIS fund investments. Available globally per Parkwalk's distribution scope and structured alongside co-investment partners such as Oxford Science Enterprises, Cambridge Enterprise, Northern Gritstone and UKI2S.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• UK Universities (Oxford, Cambridge, UCL, Manchester, etc.)coreOthersParkwalk has established relationships with major UK universities including Oxford, Cambridge, UCL, Manchester, and others to source deeptech spinout investment opportunities. The firm bridges the gap between academic innovation and commercial success.
• Oxford University InnovationcoreOthersOxford's technology transfer company that supports spinouts from the University of Oxford. Supported Scripta Therapeutics alongside Parkwalk and other investors.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Deepbridge Capital: UK-based EIS and SEIS fund manager with a focus on life sciences, technology, and renewable energy. Competes with Parkwalk for EIS-eligible UK deeptech and life sciences investments from UK HNW investors.
• Oxford Capital: UK EIS and SEIS fund manager focused on technology and growth-stage companies. Directly competes with Parkwalk in the UK EIS fund management market, serving similar HNW investor segments.
• AlbionVC: UK early-stage VC firm investing across technology and life sciences, with a strong EIS-fund offering. Co-invested alongside Parkwalk in Scripta Therapeutics and Phasecraft, directly competing for similar UK deeptech deal flow.
• Calculus Capital: London-based EIS and VCT fund manager investing in UK growth companies including technology and life sciences. Competes with Parkwalk for EIS capital from UK HNW investors targeting tax-efficient deeptech exposure.
• Northern Gritstone: University of Manchester and northern UK universities' investment vehicle targeting deeptech spinouts. Co-invested with Parkwalk in Cytotrait, competing for northern UK university spinout deal flow.
• UK Innovation & Science Seed Fund (UKI2S): A public-private seed fund focused on UK deeptech and university spinouts. Co-leads rounds with Parkwalk (e.g., K3 Metrology, Ikarovec), making it both a competitor and frequent co-investment partner for early-stage UK spinout deals.
• Oxford Science Enterprises: Oxford University's affiliated investment fund ($1.1B AUM) that invests in Oxford spinouts across deeptech and life sciences. Directly competes with Parkwalk for the same UK university spinout deal flow and co-invests with Parkwalk in companies like Quantum Motion, Brainomix, Scripta Therapeutics, and Densix.
• Cambridge Enterprise Ventures: University of Cambridge's technology transfer and investment arm that invests in Cambridge spinouts. Co-invests with Parkwalk in xWatts, Trismik, and Xen Quantum, directly competing for the same Cambridge-origin deeptech deals.

Broad incumbents

• Octopus Ventures: One of the largest UK VCs managing multiple EIS and SEIS fund products alongside growth-stage investments. A broader incumbent in the UK VC market that overlaps with Parkwalk in early-stage EIS-backed deeptech deals but operates at significantly larger scale.

Regional players

• Maven Capital Partners: UK regional VC and fund manager with VCT and EIS products across the UK regions. Operates in similar UK EIS/VCT fund management space but with a stronger regional SME focus rather than university spinouts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/park-walk-advisors
• Xx.com/ParkwalkAdvisor

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments345 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Parkwalk Advisors